{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Hematological: G4 neutropenia \\>5 days; febrile neutropenia; G\\>=3 neutropenia with infection; G4 thrombocytopenia; G3 thrombocytopenia with G\\>=2 bleeding. Non-hematological: G\\>=4 AEs; G3 CRS (except CRS events: not been maximally treated or improved to grade \\<=1 within 48 hours); G3 AEs (except: AEs attributed to CRS, G3 nausea, vomiting and diarrhea that improve to G2\\<=72 hours after maximal medical management has been initiated, G3 fatigue \\< 1 week); confirmed drug-induced liver injury meeting Hy's law criteria; G 3-4 laboratory abnormalities (except: not associated with clinical sequelae and improve to G=\\<2 within 72 hours); Other clinically important/persistent AEs (that cause significant dose delay/reduction) may be DLT; G3 injection site reaction. CTCAE version 5.0: G1: Mild AE, G2: Moderate, G3: Severe, G4: Life-threatening consequences; urgent intervention indicated, G5: Death related to AE.","groups":[{"description":"Participants with RRMM received elranatamab 12 mg SC on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1) and 32 mg on Cycle 0 Day 4 (3 days prior to Cycle 1 Day 1) \\[priming dose\\] and 44 mg on Cycle 0 Day 8 and thereafter 44 mg weekly during each cycle (1 cycle = 4 weeks) and Lenalidomide 15 mg QD for 21 days and Dexamethasone 20 mg weekly on Cycle 1 and 2.","id":"OG000","title":"SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT evaluable analysis set included all enrolled participants who received at least 1 dose of the study intervention in the Phase 1b part of the study and either experience DLT(s) or complete the DLT observation period without DLT. Participants without DLTs who received less than the minimum requirement of the planned doses of each IP were not evaluable for DLTs.","reportingStatus":"POSTED","timeFrame":"From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 42 days)","title":"SSB: Number of Participants With DLTs- Phase 1b","type":"PRIMARY","unitOfMeasure":"Participants"}